5 Stocks That Have Kicked Off the Week on a Sour Note

Page 1 of 2

Crude futures and all three indexes are lower today as investors remain in a risk-off posture before the FOMC meeting later this week and the Brexit vote on the 23rd of this month. Among the stocks deep in the red on Monday are Frontier Communications Corp (NASDAQ:FTR), Marinus Pharmaceuticals Inc (NASDAQ:MRNS), Chesapeake Energy Corporation (NYSE:CHK), ArcelorMittal SA (ADR) (NYSE:MT), and Fairmount Santrol Holdings Inc (NYSE:FMSA). Let’s find out why traders are selling off these equities and see what the smart money thinks of each stock.

Our research determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor to beat the S&P 500 by around 95 basis points per month (see the details here).

oil, rig, gas, petroleum, platform, production, petrol, sea, ocean, thailand, asia, fuel, working, water, sky, crane, cloud, power, pollution, horizontal, environmental, drill,


Technical Selling Detected at Frontier 

Frontier Communications Corp (NASDAQ:FTR) is 1.2% in the red due to technical selling. Shares of the telecom have been in a downtrend since the beginning of May and its stock price is below several key moving averages. Also hurting today’s performance is the stock’s dividend payout of $0.105 per share today, which makes the stock performance seem worse than it actually is. Of the 766 elite funds that we track, 27 funds owned $302.74 million of Frontier Communications Corp (NASDAQ:FTR) shares on March 31, down from 31 funds with $342.27 million in holdings on December 31.

Follow Frontier Communications Parent Inc. (NASDAQ:FYBR)

Marinus Drops on Study Results

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares have plunged by almost 70% after a Phase 3 trial showed that the company’s lead product candidate, Ganaxolone, failed to demonstrate statistically significant superiority over a placebo, concerning the change in seizure frequency over 28 days. Investors had hoped Ganaxolone would be a potential treatment for drug-resistant focal onset seizures in adults. Due to the results, Marinus will terminate development for that particular indication and will instead focus efforts on Ganaxolone for the potential treatment of status epilepticus and pediatric orphan seizure and behavior disorders. Three funds in our database held shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) at the end of March.

Follow Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)

On the next page we examine why Chesapeake Energy, ArcelorMittal SA (ADR), and Fairmount Santrol Holdings are losing ground today.

Page 1 of 2